These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 31121474)
1. The novel GLP-1/GIP dual receptor agonist DA3-CH is neuroprotective in the pilocarpine-induced epileptogenesis rat model. Tian MJ; Wang RF; Hölscher C; Mi RL; Yuan ZY; Li DF; Xue GF Epilepsy Res; 2019 Aug; 154():97-106. PubMed ID: 31121474 [TBL] [Abstract][Full Text] [Related]
2. The novel GLP-1/GIP dual agonist DA3-CH is more effective than liraglutide in reducing endoplasmic reticulum stress in diabetic rats with cerebral ischemia-reperfusion injury. Bai B; Li D; Xue G; Feng P; Wang M; Han Y; Wang Y; Hölscher C Nutr Metab Cardiovasc Dis; 2021 Jan; 31(1):333-343. PubMed ID: 33500109 [TBL] [Abstract][Full Text] [Related]
3. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease. Yuan Z; Li D; Feng P; Xue G; Ji C; Li G; Hölscher C Eur J Pharmacol; 2017 Oct; 812():82-90. PubMed ID: 28666800 [TBL] [Abstract][Full Text] [Related]
4. A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat. Han L; Hölscher C; Xue GF; Li G; Li D Neuroreport; 2016 Jan; 27(1):23-32. PubMed ID: 26555034 [TBL] [Abstract][Full Text] [Related]
5. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. Shi L; Zhang Z; Li L; Hölscher C Behav Brain Res; 2017 Jun; 327():65-74. PubMed ID: 28342971 [TBL] [Abstract][Full Text] [Related]
6. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF. Ji C; Xue GF; Lijun C; Feng P; Li D; Li L; Li G; Hölscher C Brain Res; 2016 Mar; 1634():1-11. PubMed ID: 26453833 [TBL] [Abstract][Full Text] [Related]
7. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease. Zhang L; Zhang L; Li Y; Li L; Melchiorsen JU; Rosenkilde M; Hölscher C J Parkinsons Dis; 2020; 10(2):523-542. PubMed ID: 31958096 [TBL] [Abstract][Full Text] [Related]
8. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease. Salles GN; Calió ML; Hölscher C; Pacheco-Soares C; Porcionatto M; Lobo AO Neuropharmacology; 2020 Jan; 162():107813. PubMed ID: 31628935 [TBL] [Abstract][Full Text] [Related]
9. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease. Jalewa J; Sharma MK; Gengler S; Hölscher C Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210 [TBL] [Abstract][Full Text] [Related]
10. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease. Feng P; Zhang X; Li D; Ji C; Yuan Z; Wang R; Xue G; Li G; Hölscher C Neuropharmacology; 2018 May; 133():385-394. PubMed ID: 29462693 [TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease. Tai J; Liu W; Li Y; Li L; Hölscher C Brain Res; 2018 Jan; 1678():64-74. PubMed ID: 29050859 [TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease. Ji C; Xue GF; Li G; Li D; Hölscher C Rev Neurosci; 2016 Jan; 27(1):61-70. PubMed ID: 26351802 [TBL] [Abstract][Full Text] [Related]
13. Neuroprotection of GLP-1/GIP receptor agonist via inhibition of mitochondrial stress by AKT/JNK pathway in a Parkinson's disease model. Li T; Tu L; Gu R; Yang XL; Liu XJ; Zhang GP; Wang Q; Ren YP; Wang BJ; Tian JY Life Sci; 2020 Sep; 256():117824. PubMed ID: 32445758 [TBL] [Abstract][Full Text] [Related]
14. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models. Hölscher C Neuropharmacology; 2018 Jul; 136(Pt B):251-259. PubMed ID: 29402504 [TBL] [Abstract][Full Text] [Related]
15. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain. Cao L; Li D; Feng P; Li L; Xue GF; Li G; Hölscher C Neuroreport; 2016 Apr; 27(6):384-91. PubMed ID: 26918675 [TBL] [Abstract][Full Text] [Related]
16. Treatment with CCR2 antagonist is neuroprotective but does not alter epileptogenesis in the pilocarpine rat model of epilepsy. Foresti ML; Arisi GM; Campbell JJ; Mello LE Epilepsy Behav; 2020 Jan; 102():106695. PubMed ID: 31785482 [TBL] [Abstract][Full Text] [Related]
17. The novel GLP-1/GIP dual agonist DA3-CH improves rat type 2 diabetes through activating AMPK/ACC signaling pathway. Xu J; Chen P; Wu D; Zhou Q; Chen S; Ding X; Xiong H Aging (Albany NY); 2023 Oct; 15(20):11152-11161. PubMed ID: 37851373 [TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory treatment with a soluble epoxide hydrolase inhibitor attenuates seizures and epilepsy-associated depression in the LiCl-pilocarpine post-status epilepticus rat model. Shen Y; Peng W; Chen Q; Hammock BD; Liu J; Li D; Yang J; Ding J; Wang X Brain Behav Immun; 2019 Oct; 81():535-544. PubMed ID: 31306773 [TBL] [Abstract][Full Text] [Related]
19. Post-treatment with the GLP-1 analogue liraglutide alleviate chronic inflammation and mitochondrial stress induced by Status epilepticus. Wang RF; Xue GF; Hölscher C; Tian MJ; Feng P; Zheng JY; Li DF Epilepsy Res; 2018 May; 142():45-52. PubMed ID: 29549796 [TBL] [Abstract][Full Text] [Related]
20. The novel GLP-1/GIP analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD. Li C; Liu W; Li X; Zhang Z; Qi H; Liu S; Yan N; Xing Y; Hölscher C; Wang Z Brain Behav; 2020 Mar; 10(3):e01505. PubMed ID: 31960630 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]